References
1. The pandemic’s impact on the pediatric cancer research landscape. 2020. (Accessed April 28, 2020, at http://solvingkidscancer.org/covid19webinar/.)
2. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med 2015;373:1541-52.
3. Cancer Facts & Figures 2020. American Cancer Society. at https://www.cancer.org/cancer/cancer-in-children/key-statistics.html#references.)
4. Yeh JM, Ward ZJ, Chaudhry A, et al. Life Expectancy of Adult Survivors of Childhood Cancer Over 3 Decades. JAMA Oncol 2020.
5. Coronavirus disease (COVID-19) situation reports. 2020. at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.)
6. Van de Haar J, Hoes LR, Coles CE, et al. Caring for patients with cancer in the COVID-19 era. Nat Medicine 2020.
7. COVID-19: Open letter to cancer researchers. 2020. (Accessed April 6, 2020, at https://www.cancerresearchuk.org/funding-for-researchers/research-features/2020-04-06-covid-19-open-letter-to-cancer-researchers?utm_source=proactivestatement&utm_campaign=rbc_covid19_researcheropenletter.)
8. Cancer Research UK response to government’s charity package. 2020. (Accessed April 8, 2020, at https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2020-04-08-cancer-research-uk-response-to-governments-charity-package.)
9. Excellence NIfHaC. COVID-19 rapid guideline: children and young people who are immunocompromised May 1, 2020.
10. Dong Y, Mo X, Hu Y, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics 2020.
11. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep 39:343-6.
12. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J 2020.
13. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep;69:382-6.
14. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep;69:422-6.
15. Liu Y, Yan LM, wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020.
16. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020.
17. Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nature Medicine 2020.
18. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020.
19. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4.
20. Mejias A, Dimo B, Suarez NM, et al. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med 2013;10:e1001549.
21. Garcia-Salido A. Three hypotheses about children COVID19. Pediatr Infect Dis J 2020.
22. PICS statement regarding novel presentation of multi-system inflammatory disease. 2020. (Accessed April 27, 2020, at https://picsociety.uk/news/pics-statement-regarding-novel-presentation-of-multi-system-inflammatory-disease/.)
23. Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. Hosp Pediatr 2020.
24. Turnier JL, Anderson MS, Heizer HR, Jone PN, Glode MP, Dominguez SR. Concurrent Respiratory Viruses and Kawasaki Disease. Pediatrics 2015;136:e609-14.
25. Kam KQ, Yung CF, Cui L, et al. A Well Infant with Coronavirus Disease 2019 (COVID-19) with High Viral Load. Clin Infect Dis 2020.
26. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nature Medicine 2020.
27. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity 2012;37:771-83.
28. van den Broek T, Borghans JAM, van Wijk F. The full spectrum of human naive T cells. Nat Rev Immunol 2018;18:363-73.
29. Prendergast AJ, Klenerman P, Goulder PJ. The impact of differential antiviral immunity in children and adults. Nat Rev Immunol 2012;12:636-48.
30. McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol 2015;15:87-103.
31. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012;12:125-35.
32. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and exacerbated inflammatory response to in severe COVID-19 patients. MedRxiv 2020.
33. Trouillet-Assant S, Viel S, Gaymard A, et al. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol 2020.
34. Heinonen S, Velazquez VM, Ye F, et al. Immune profiles provide insights into respiratory syncytial virus disease severity in young children. Sci Transl Med 2020;12.
35. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020.
36. Goldszmid RS, Dzutsev A, Trinchieri G. Host immune response to infection and cancer: unexpected commonalities. Cell Host Microbe 2014;15:295-305.
37. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013;13:759-71.
38. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol 2015;15:405-14.
39. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 2017;17:97-111.
40. Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol 2011;2:98.
41. Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer. Immunity 2018;48:812-30 e14.
42. Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia 2014;28:1467-71.
43. Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol 2018;99:619-30.
44. Martin PJ. How I treat steroid-refractory acute graft-versus-host disease. Blood 2020.
45. Neelapu SS, Tummala S, Kebriaei P, et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit ’ALL’. Nat Rev Clin Oncol 2018;15:218.
46. Snell LM, McGaha TL, Brooks DG. Type I Interferon in Chronic Virus Infection and Cancer. Trends Immunol 2017;38:542-57.
47. Martinez MA. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Antimicrob Agents Chemother 2020;64.
48. Gold JA, Wong KK, Szablewki CM, et al. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020. MMWR Morb Mortal Wkly Rep.
49. IFS Deaton Review: Are some ethnic groups more vulnerable to COVID-19 than others? Institute for Fiscal Studies, 2020. at https://www.ifs.org.uk/inequality/chapter/are-some-ethnic-groups-more-vulnerable-to-covid-19-than-others/.)
50. Francis SS, Wallace AD, Wendt GA, et al. In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia. Blood 2017;129:1680-4.